HRAS Antibody (Center) Blocking Peptide
€363.00
In stock
SKU
AC-BP7764c
Background:
HRAS belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. These proteins function in signal transduction pathways. They can bind GTP and GDP, and they have intrinsic GTPase activity. HRAS undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in the HRAS gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.
Other Names:
GTPase HRas, H-Ras-1, Ha-Ras, Transforming protein p21, c-H-ras, p21ras, GTPase HRas, N-terminally processed, HRAS, HRAS1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7764c was selected from the Center region of human HRAS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: HRAS
Gene ID: 3265
Primary Accession: P01112
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
HRAS belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. These proteins function in signal transduction pathways. They can bind GTP and GDP, and they have intrinsic GTPase activity. HRAS undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in the HRAS gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.
Other Names:
GTPase HRas, H-Ras-1, Ha-Ras, Transforming protein p21, c-H-ras, p21ras, GTPase HRas, N-terminally processed, HRAS, HRAS1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7764c was selected from the Center region of human HRAS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: HRAS
Gene ID: 3265
Primary Accession: P01112
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review